Retroversion in Reverse Shoulder Arthroplasty
Launched by HOSPITAL UNIVERSITARIO REINA SOFIA DE CORDOBA · Mar 24, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a type of shoulder surgery called reverse shoulder arthroplasty (RSA) to help people with shoulder osteoarthritis. Specifically, the study aims to find out if using a higher angle of retroversion (which is the backward tilt of the shoulder bone) during surgery can improve how well patients can rotate their arm outward. Participants will be randomly assigned to receive either a 0-degree or a 30-degree angle for their surgery, and their progress will be monitored for two years.
To be eligible for the trial, participants need to be over 60 years old and have primary rotator cuff arthropathy, which means they have wear and tear on the shoulder's muscles and tendons. Unfortunately, those who have had previous shoulder surgeries or have post-traumatic arthropathy (shoulder issues caused by an injury) cannot participate. If you join the trial, you can expect regular check-ups to track your recovery and function over the two years, helping researchers understand which surgery angle might work better for improving shoulder movement.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients \> 60 years
- • primary rotator cuff arthropathy
- • implantation of reverse shoulder arthroplasty
- Exclusion Criteria:
- • previous surgeries in the shoulder
- • post-traumatic arthropathy
About Hospital Universitario Reina Sofia De Cordoba
Hospital Universitario Reina Sofía de Córdoba is a leading academic medical center in Spain, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise and state-of-the-art facilities to facilitate groundbreaking research across various medical disciplines. The institution is dedicated to improving patient outcomes by fostering collaboration among healthcare professionals, researchers, and academic institutions, ensuring that cutting-edge treatments and therapies are developed and made accessible to patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Córdoba, Cordoba, Spain
Patients applied
Trial Officials
Jose Carlos Minarro, Dr
Principal Investigator
Hospital Universitario Reina Sofía de Córdoba
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials